Sign In

Login

Password

Forgot Password ? Sign Up

Naltrexon (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Naltrexon" in German language version.

refsWebsite
Global rank German rank
14doi.org
2nd place
3rd place
12nih.gov
4th place
7th place
1sigmaaldrich.com
924th place
87th place
1web.archive.org
1st place
1st place
1redirecter.toolforge.org
33rd place
2nd place
1aacp.com
low place
low place
1ldnresearchtrust.org
low place
low place
1dovepress.com
low place
8,392nd place
1lww.com
2,769th place
2,484th place

aacp.com

doi.org

  • Lobmaier P, Kornør H, Kunøe N, Bjørndal A: Sustained-release naltrexone for opioid dependence. In: Cochrane Database Syst Rev. Nr. 2, 2008, S. CD006140, doi:10.1002/14651858.CD006140.pub2, PMID 18425938 (englisch).
  • Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. In: Cochrane Database Syst Rev. Nr. 1, 2006, S. CD001333, doi:10.1002/14651858.CD001333.pub2, PMID 16437431 (englisch).
  • Wilfrid Noel Raby, PhD, MD, Kenneth M. Carpenter, PhD, Jami Rothenberg, PhD, Adam C. Brooks, PhD, Huiping Jiang, PhD, Maria Sullivan, MD, Adam Bisaga, MD, Sandra Comer, PhD, and Edward V. Nunes, MD: "Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence" Am J Addict. 2009 Jul–Aug; 18(4): 301–308. doi:10.1080/10550490902927785; PMC 2753886 (freier Volltext).
  • Minozzi S, Amato L, Davoli M: Detoxification treatments for opiate dependent adolescents. In: Cochrane Database Syst Rev. Nr. 2, 2009, S. CD006749, doi:10.1002/14651858.CD006749.pub2, PMID 19370651 (englisch).
  • Igho J. Onakpoya, Joseph J. Lee, Kamal R. Mahtani, Jeffrey K. Aronson, Carl J. Heneghan: Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports. In: British Journal of Clinical Pharmacology. Band 86, Nr. 4, April 2020, S. 646–667, doi:10.1111/bcp.14210, PMID 31918448, PMC 7098870 (freier Volltext) – (englisch).
  • Symons FJ, Thompson A, Rodriguez MC: Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. In: Ment Retard Dev Disabil Res Rev. 10. Jahrgang, Nr. 3, 2004, S. 193–200, doi:10.1002/mrdd.20031, PMID 15611982 (englisch).
  • Rachel Cant, Angus G. Dalgleish, Rachel L. Allen: Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. In: Frontiers in Immunology. Band 8, 2017, doi:10.3389/fimmu.2017.00809, PMID 28744288, PMC 5504148 (freier Volltext) – (englisch).
  • Natalia Kučić, Valentino Rački, Roberta Šverko, Toni Vidović, Irena Grahovac, Jasenka Mršić-Pelčić: Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. In: International Journal of Molecular Sciences. Band 22, Nr. 16, Januar 2021, S. 8429, doi:10.3390/ijms22168429, PMID 34445130, PMC 8395119 (freier Volltext) – (englisch).
  • Lie, M.R.K.L., van der Giessen, J., Fuhler, G.M. et al.: Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med, abgerufen am 3. April 2024 (englisch).
  • Jill P. Smith, Heather Stock, Sandra Bingaman, David Mauger, Moshe Rogosnitzky, Ian S. Zagon: Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. In: Official journal of the American College of Gastroenterology | ACG. Band 102, Nr. 4, April 2007, S. 820, doi:10.1111/j.1572-0241.2007.01045.x (englisch, lww.com [abgerufen am 3. April 2024]).
  • M Gironi, F Martinelli-Boneschi, P Sacerdote, C Solaro, M Zaffaroni, R Cavarretta, L Moiola, S Bucello, M Radaelli, V Pilato, Me Rodegher, M Cursi, S Franchi, V Martinelli, R Nemni, G Comi, G Martino: A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. In: Multiple Sclerosis Journal. Band 14, Nr. 8, September 2008, S. 1076–1083, doi:10.1177/1352458508095828 (englisch).
  • Olli Polo, Pia Pesonen, Essi Tuominen: Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, Health & Behavior. Band 7, Nr. 4, 2. Oktober 2019, S. 207–217, doi:10.1080/21641846.2019.1692770 (englisch).
  • Jarred Younger, Luke Parkitny, David McLain: The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. In: Clinical Rheumatology. Band 33, Nr. 4, 1. April 2014, S. 451–459, doi:10.1007/s10067-014-2517-2, PMID 24526250, PMC 3962576 (freier Volltext) – (englisch).
  • Hector Bonilla, Lu Tian, Vincent C. Marconi, Robert Shafer, Grace A. McComsey, Mitchel Miglis, Philip Yang, Andres Bonilla, Lauren Eggert, Linda N. Geng: Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. In: International Immunopharmacology. Band 124, November 2023, S. 110966, doi:10.1016/j.intimp.2023.110966 (englisch).

dovepress.com

ldnresearchtrust.org

lww.com

journals.lww.com

  • Jill P. Smith, Heather Stock, Sandra Bingaman, David Mauger, Moshe Rogosnitzky, Ian S. Zagon: Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. In: Official journal of the American College of Gastroenterology | ACG. Band 102, Nr. 4, April 2007, S. 820, doi:10.1111/j.1572-0241.2007.01045.x (englisch, lww.com [abgerufen am 3. April 2024]).

nih.gov

ncbi.nlm.nih.gov

  • Lobmaier P, Kornør H, Kunøe N, Bjørndal A: Sustained-release naltrexone for opioid dependence. In: Cochrane Database Syst Rev. Nr. 2, 2008, S. CD006140, doi:10.1002/14651858.CD006140.pub2, PMID 18425938 (englisch).
  • Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. In: Cochrane Database Syst Rev. Nr. 1, 2006, S. CD001333, doi:10.1002/14651858.CD001333.pub2, PMID 16437431 (englisch).
  • Adi Y, Juarez-Garcia A, Wang D, et al.: Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. In: Health Technol Assess. 11. Jahrgang, Nr. 6, Februar 2007, S. iii–iv, 1–85, PMID 17280624 (englisch, hta.ac.uk (Memento des Originals vom 17. November 2011 im Internet Archive) [abgerufen am 1. Juli 2009]).
  • Wilfrid Noel Raby, PhD, MD, Kenneth M. Carpenter, PhD, Jami Rothenberg, PhD, Adam C. Brooks, PhD, Huiping Jiang, PhD, Maria Sullivan, MD, Adam Bisaga, MD, Sandra Comer, PhD, and Edward V. Nunes, MD: "Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence" Am J Addict. 2009 Jul–Aug; 18(4): 301–308. doi:10.1080/10550490902927785; PMC 2753886 (freier Volltext).
  • Minozzi S, Amato L, Davoli M: Detoxification treatments for opiate dependent adolescents. In: Cochrane Database Syst Rev. Nr. 2, 2009, S. CD006749, doi:10.1002/14651858.CD006749.pub2, PMID 19370651 (englisch).
  • Igho J. Onakpoya, Joseph J. Lee, Kamal R. Mahtani, Jeffrey K. Aronson, Carl J. Heneghan: Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports. In: British Journal of Clinical Pharmacology. Band 86, Nr. 4, April 2020, S. 646–667, doi:10.1111/bcp.14210, PMID 31918448, PMC 7098870 (freier Volltext) – (englisch).
  • Symons FJ, Thompson A, Rodriguez MC: Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. In: Ment Retard Dev Disabil Res Rev. 10. Jahrgang, Nr. 3, 2004, S. 193–200, doi:10.1002/mrdd.20031, PMID 15611982 (englisch).
  • Rachel Cant, Angus G. Dalgleish, Rachel L. Allen: Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. In: Frontiers in Immunology. Band 8, 2017, doi:10.3389/fimmu.2017.00809, PMID 28744288, PMC 5504148 (freier Volltext) – (englisch).
  • Natalia Kučić, Valentino Rački, Roberta Šverko, Toni Vidović, Irena Grahovac, Jasenka Mršić-Pelčić: Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. In: International Journal of Molecular Sciences. Band 22, Nr. 16, Januar 2021, S. 8429, doi:10.3390/ijms22168429, PMID 34445130, PMC 8395119 (freier Volltext) – (englisch).
  • Jarred Younger, Luke Parkitny, David McLain: The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. In: Clinical Rheumatology. Band 33, Nr. 4, 1. April 2014, S. 451–459, doi:10.1007/s10067-014-2517-2, PMID 24526250, PMC 3962576 (freier Volltext) – (englisch).

chem.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

redirecter.toolforge.org

  • Adi Y, Juarez-Garcia A, Wang D, et al.: Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. In: Health Technol Assess. 11. Jahrgang, Nr. 6, Februar 2007, S. iii–iv, 1–85, PMID 17280624 (englisch, hta.ac.uk (Memento des Originals vom 17. November 2011 im Internet Archive) [abgerufen am 1. Juli 2009]).

sigmaaldrich.com

web.archive.org

  • Adi Y, Juarez-Garcia A, Wang D, et al.: Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. In: Health Technol Assess. 11. Jahrgang, Nr. 6, Februar 2007, S. iii–iv, 1–85, PMID 17280624 (englisch, hta.ac.uk (Memento des Originals vom 17. November 2011 im Internet Archive) [abgerufen am 1. Juli 2009]).